[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: Patients diagnosed with COVID-19 who receiving standard care including Kaletra or hydroxychloroquine, naproxen and other accessory drugs.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: Patients diagnosed with COVID-19 who receiving the standard care including Kaletra or hydroxychloroquine, naproxen and other accessory drugs as well as MAB98 including 125 and 250 mgr capsules received 2 and 3 times daily, respectively for 6 (outpatients) or 12 days (inpatients). MAB98 consisting of extracted colchicine-rich fraction of Colchicum autumnale, as well as thymoquinone and thymol rich fractions of Nigella Sativa and Trachyspermum Ammi respectively which their effective components have been extracted through alcoholic and water extraction. MAB98 was manufacture in the Zist Tolid Razi Co.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2198, "treatment_name": "Colchicine+thymol+thymoquinone", "treatment_type": "Metabolic agents+others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]